Search results
Results from the WOW.Com Content Network
Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. [4] It is taken by mouth. [ 4 ] Use is often recommended together with vitamin D , calcium supplementation , and lifestyle changes.
This type of drug has a high affinity for hydroxyapatite [28] and stays in bone tissue for a long period of time, [29] with alendronate, it has a half-life of approximately ten years. [30] The risk of a patient having MRONJ after discontinuing this medication is unknown. [30]
[5] [10] [11] [12] Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [ 2 ] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% ...
The body of a woman who disappeared 10 years ago has been found in a minivan submerged in a Florida pond. Yekaterina “Katya” Belaya, a mom of three, was last seen heading to a store in 2014 ...
Sara was found dead at the family’s home in Woking, U.K., a town southwest of London, on Aug. 10, 2023, with multiple injuries including broken bones, burns, bruising and a traumatic head injury ...
Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women. [ 3 ] [ 2 ] [ 4 ] [ 6 ] Alendronic acid/colecalciferol was approved for use in the United States and in the European Union in 2005.
For the first time in over a decade, obesity rates in the United States may finally be heading in the right direction and new weight loss drugs like semaglutide could be part of the reason why. A ...
The International Myeloma Foundation's web-based survey included 1203 respondents, 904 patients with myeloma and 299 with breast cancer and an estimate that after 36 months, osteonecrosis of the jaw had been diagnosed in 10% of 211 patients on zoledronate and 4% of 413 on pamidronate. [16]